[1]刘文,魏芳晶.药物涂层球囊在分叉病变中的应用[J].国际心血管病杂志,2022,06:321-325.
点击复制
药物涂层球囊在分叉病变中的应用(PDF)
《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]
- 期数:
- 2022年06期
- 页码:
- 321-325
- 栏目:
- 综述
- 出版日期:
- 2022-12-20
文章信息/Info
- Title:
- -
- Author(s):
- -
- Keywords:
- -
- 分类号:
- -
- DOI:
- 10.3969/j.issn.1673-6583.2022.06.001
- 文献标识码:
- -
- 摘要:
- 冠状动脉分叉病变在临床经皮冠状动脉介入术中占比高（15%～20%），经皮冠 状动脉介入术为其主要治疗方式。分叉病变解剖结构复杂，手术操作难度高，术后再狭窄及 支架内血栓的发生率高，属于复杂冠状动脉病变，是经皮冠状动脉介入术的难点。药物涂层 球囊因操作简便，长期抑制血管内膜增生，无植入物残留，且可保留再次治疗机会，被广泛用 于小血管病变及支架内再狭窄，药物涂层球囊探索性治疗已延伸至分叉病变，为分叉病变的 治疗带来更多选择。药物洗脱支架与药物涂层球囊的联合应用、单纯应用药物涂层球囊以 及药物涂层球囊与其他技术的联合应用（可降解支架、冠脉粥样硬化切除术）已经展现出 良好的临床效益。尽管药物涂层球囊治疗分叉病变存在价格昂贵、无明确的手术策略、缺 乏更多优质试验验证临床效果、对特殊情况的分叉病变研究较少等问题，但药物涂层球囊在 治疗分叉病变中仍然有着巨大潜力。
- Abstract:
- -
参考文献/References
[1] Bogana Shanmugam V, Psaltis PJ, Tay L, et al. Procedural and
clinical outcomes in management of bifurcational lesions in
ST elevation myocardial infarction[J]. Heart Lung Circ, 2020,
29(2):272-279.
[2] ElwanyM, PalmaGD, Cortese B. Treatment of coronary
bi furcat ion les ions :cur rent knowledge and future
perspectives[J]. Future Cardiol, 2018, 14(2):165-179.
[3] Arslani K, Jeger R. Drug-coated balloons for small coronary
disease—a literature review[J]. Curr Cardiol Rep, 2021,
23(11):1-7.
[4] Scheller B, Ohlow MA, Ewen S, et al. Bare metal or drugeluting
stent versus drug-coated balloon in non-ST-elevation
myocardial infarction: the randomised PEPCAD NSTEMI
trial[J]. Euro Intervention, 2020, 15(17):1527-1533.
[5] Uskela S, K?rkk?inen JM, Er?nen J, et al. Percutaneous
coronary intervention with drug-coated balloon-only strategy
in stable coronary artery disease and in acute coronary
syndromes: an all-comers registry study[J]. Catheter
Cardiovasc Interv, 2019, 93(5):893-900.
[6] Rissanen TT, Uskela S, Er?nen J, et al. Drug-coated balloon
for treatment of de-novo coronary artery lesions in patients
with high bleeding risk (DEBUT): a single-blind, randomised,
non-inferiority trial[J]. Lancet, 2019, 394(10194):230-239.
[7] Jeger RV, Farah A, Ohlow MA, et al. Drug-coated balloons
for small coronary artery disease (BASKET-SMALL 2): an
open-label randomised non-inferiority trial[J]. Lancet, 2018,
392(10150):849-856.
[8] Lassen JF, Albiero R, Johnson TW, et al. Treatment of
coronary bifurcation lesions, part Ⅱ: implanting two stents.
The 16th expert consensus document of the European
Bifurcation Club[J]. Euro Intervention, 2022, 18(6):457-470.
[9] Kumsars I, Holm NR, Niemel? M, et al. Randomised
comparison of provisional side branch stenting versus a twostent
strategy for treatment of true coronary bifurcation lesions
involving a large side branch: the Nordic-Baltic Bifurcation
Study Ⅳ[J]. Open Heart, 2020, 7(1): e000947.
[10] Mathey DG, Wendig I, Boxberger M, et al. Treatment of
bifurcation lesions with a drug-eluting balloon: the PEPCAD Ⅴ
(Paclitaxel Eluting PTCA Balloon in Coronary Artery Disease)
trial[J]. Euro Intervention, 2011, 7:K61-K65.
[11] Jing QM, Zhao X, Han YL, et al. A drug-eluting Balloon for
the trEatment of coronarYbifurcatiON lesions in the side
branch: a prospective multicenter ranDomized (BEYOND)
clinical trial in China[J]. Chin Med J (Engl), 2020, 133(8):899-
908.
[12] Berland J, Lefèvre T, Brenot P, et al. DANUBIO—a new
drug-eluting balloon for the treatment of side branches in
bifurcation lesions: six-month angiographic follow-up results
of the DEBSIDE trial[J]. Euro Intervention, 2015, 11(8):868-
876.
[13] 卜金钟, 戚金威, 汪亨通, 等. 药物洗脱球囊对冠状动脉真
性分叉病变分支保护作用研究[J]. 临床军医杂志, 2021,
49(3):285-287.
[14] Li Y, Mao Q, Liu H, et al. Effect of paclitaxel-coated balloon
angioplasty on side branch lesion and cardiovascular outcomes
in patients with de novo true coronary bifurcation lesions
undergoing percutaneous coronary intervention[J]. Cardiovasc
Drugs Ther, 2021, 36(5):859-866.
[15] Zhang JJ, Ye F, Xu K, et al. Multicentre, randomized
comparison of two-stent and provisional stenting techniques
in patients with complex coronary bifurcation lesions: the
DEFINITION Ⅱ trial[J]. Eur Heart J, 2020, 41(27):2523-
2536.
[16] Crimi G, Mandurino-Mirizzi A, Gritti V, et al. Percutaneous
coronary intervention techniques for bifurcation disease:
network meta-analysis reveals superiority of double-kissing
crush[J]. Can J Cardiol, 2020, 36(6):906-914.
[17] Hildick-Smith D, Egred M, Banning A, et al. The European
bifurcation club Left Main Coronary Stent study: a randomized
comparison of stepwise provisional vs. systematic dual
stenting strategies (EBC MAIN)[J]. Eur Heart J, 2021, 42(37):
3829-3839.
[18] Stella PR, Belkacemi A, Dubois C, et al. A multicenter
randomized comparison of drug-eluting balloon plus baremetal stent versus bare-metal stent versus drug-eluting stent
in bifurcation lesions treated with a single-stenting technique:
six-month angiographic and 12-month clinical results of
the drug-eluting balloon in bifurcations trial[J]. Catheter
Cardiovasc Interv, 2012, 80(7):1138-1346.
[19] Colombo A, Leone PP. Treating bifurcation lesions: the result
overcomes the technique[J]. JACC Cardiovasc Interv, 2021,
14(21):2327-2329.
[20] García-Escobar A, Jurado-Román A, Jiménez-Valero S, et
al. Clinical outcomes of drug-eluting balloon for treatment
of small coronary artery in patients with acute myocardial
infarction: comment[J]. Intern Emerg Med, 2021, 16(4):1099-
1100.
[21] 邱竞, 韩战营, 王玺, 等. 药物包被球囊治疗冠状动脉大
血管原位病变的疗效观察[J]. 中华心血管病杂志, 2019,
47(6):452-456.
[22] Schulz A, Hauschild T, Kleber FX. Treatment of coronary de
novo bifurcation lesions with DCB only strategy[J]. Clin Res
Cardiol, 2014, 103(6):451-456.
[23] Kleber FX, Rittger H, Ludwig J, et al. Drug eluting balloons
as stand alone procedure for coronary bifurcational lesions:
results of the randomized multicenter PEPCAD-BIF trial[J].
Clin Res Cardiol, 2016, 105(7):613-621.
[24] Bruch L, Zadura M, Waliszewski M, et al. Results from the
international drug coated balloon registry for the treatment of
bifurcations. Can a bifurcation be treated without stents?[J]. J
Interv Cardiol, 2016, 29(4):348-356.
[25] Buiten RA, Warta S, Ploumen EH, et al. Coronary bifurcations
treated with thin-strut drug-eluting stents: a prespecified
analysis of the randomized BIO-RESORT trial[J]. Coron
Artery Dis, 2020, 32(1):51-57.
[26] Piraino D, Carella M, Buccheri D, et al. Bifurcation lesions:
bioresorbable vascular scaffold and drug coated balloon,
an efficacy association. Lessons from optimal coherence
tomography[J]. Int J Cardiol, 2016, 212:92-93.
[27] Elwany M, Zaki A, Latib A, et al. The impact of the use of
bioresorbable vascular scaffolds and drug-coated balloons in
coronary bifurcation lesions[J]. Egypt Heart J, 2019, 71(1):31.
[28] Kitani S, Igarashi Y, Tsuchikane E, et al. Efficacy of drugcoated
balloon angioplasty after directional coronary
atherectomy for coronary bifurcation lesions (DCA/DCB
registry)[J]. Catheter Cardiovasc Interv, 2021, 97(5):
E614-E623.
[29] Okutsu M, Mitomo S, Ouchi T, et al. Impact of directional
coronary atherectomy followed by drug-coated balloon
strategy to avoid the complex stenting for bifurcation
lesions[J]. Heart Vessels, 2022, 37(6):919-930.
备注/Memo
- 备注/Memo:
-
基金项目：内蒙古自治区高等学校重大科学研究项目（NJZZ21033）
通信作者：魏芳晶，E-mail：nmgfywfj@sohu.com
常用功能
统计/Statistics
- 摘要浏览/Viewed85
- 全文下载/Downloads461
- 评论/Comments
